RENOVA, Inc. 9519
TSE · Japan · Utilities
¥825.00-22.00 (-2.60%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Renova Pharmaceuticals LLC ("Renova"), a U.S.-based pharmaceutical company focused on bringing high-quality and affordable generic medicines to patients, today announced the commercial launch of its first three FDA-approved generic products in the United States: L-Glutamine for Oral Solution, Dimethyl Sulfoxide (DMSO) Irrigation, 50%, and Ascorbic Acid Injection.
Renova Technology, Inc. is proud to announce that it is now a member of the Association of Gaming Equipment Manufacturers (AGEM). The membership provides Renova with a stronger sense of community in the gaming industry, where it provides services to manufacturers of gaming and lottery hardware. As an AGEM member, Renova will stay ahead of industry trends from leaders, including top regulators and government officials. AGEM addresses worldwide business, legislative, regulatory, and expansion issu
Renova Technology, Inc., an award-winning technology services and supply chain provider, has established a strategic service agreement with Nanolumens, a US-based LED manufacturer offering innovative display solutions across multiple market segments including transportation hubs, universities, corporate offices, and themed entertainment venues.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.